OCTOBER 7, 2021 – The World Health Organization yesterday announced its recommendation for RTS,S – the only approved malaria vaccine (also known as Mosquirix) – for mass distribution in Africa, marking a significant milestone in the fight against one of the leading causes of death for children under five in the region.
Despite being preventable and treatable, malaria kills approximately 260,000 African children under the age of five every year. Developed by one of HPIC’s founding members, GlaxoSmithKline (GSK), the RTS,S vaccine was developed in Africa by African scientists following nearly a decade of clinical trials in seven countries.
HPIC welcomes this significant development in the fight against malaria and is proud to continue to support innovation in Africa through its ongoing partnership with GSK.
To learn more about HPIC’s work in the prevention and treatment of malaria and other preventable diseases in Africa, read about our HOPE project here.
Related to Health Partners International of Canada welcomes the development of the first approved malaria vaccine
HPIC & Anera Partner to Support Premature Neonates in Lebanon
September 29, 2022 | OAKVILLE, ON – A shipment of specialized medicines that will provide treatment to preterm newborns in…
Health Partners International of Canada rallies local community and pharmaceutical industry for large shipment to help the people of Ukraine
OAKVILLE, ON, April 18, 2022 – Health Partners International of Canada (HPIC), an Oakville-based charity that works to improve access…
Health Partners International of Canada announces Lois Brown as President
OAKVILLE, ON. – Today, Health Partners International of Canada (HPIC), a Canadian charity that works globally to increase access to…